TOPLINE:

Healthy older adults who received aspirin experienced no significant long-term benefits against major adverse cardiovascular events (MACE); the rates of major hemorrhage were higher among users of aspirin than among users of placebo.

METHODOLOGY:

Guidelines advise against routine initiation of aspirin for primary prevention of atherosclerotic cardiovascular disease events in older adults, yet many continue to use it. The long-term effects of using aspirin in this population remain uncertain.

Researchers analyzed data from 15,668 older adults from Australia and the US who took part in the ASPREE trial (median age at the end of the trial, 79 years; 43.1% men) to assess the post-trial and long-term effects of aspirin on cardiovascular events.

At enrollment, the participants had

See Full Page